Zhiyuan Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10902557/publications.pdf

Version: 2024-02-01

35	3,645 citations	218677 26 h-index	35 g-index
papers	Citations	II-IIIQEX	g-muex
35 all docs	35 docs citations	35 times ranked	5960 citing authors

#	Article	IF	CITATIONS
1	Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4402-4407.	7.1	1,089
2	Boosting the down-shifting luminescence of rare-earth nanocrystals for biological imaging beyond 1500 nm. Nature Communications, 2017, 8, 737.	12.8	416
3	Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12624-12629.	7.1	237
4	Label-Free Quantitative Detection of Tumor-Derived Exosomes through Surface Plasmon Resonance Imaging. Analytical Chemistry, 2014, 86, 8857-8864.	6.5	211
5	Brain fatty acid synthase activates PPARÎ \pm to maintain energy homeostasis. Journal of Clinical Investigation, 2007, 117, 2539-2552.	8.2	183
6	Pathologicalâ€Conditionâ€Driven Construction of Supramolecular Nanoassemblies for Bacterial Infection Detection. Advanced Materials, 2016, 28, 254-262.	21.0	159
7	Molecular Cancer Imaging in the Second Nearâ€Infrared Window Using a Renalâ€Excreted NIRâ€II Fluorophoreâ€Peptide Probe. Advanced Materials, 2018, 30, e1800106.	21.0	115
8	A Role for Hypothalamic Malonyl-CoA in the Control of Food Intake. Journal of Biological Chemistry, 2005, 280, 39681-39683.	3.4	110
9	Inhibition of hypothalamic fatty acid synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14557-14562.	7.1	91
10	Energy Migration Engineering of Bright Rareâ€Earth Upconversion Nanoparticles for Excitation by Lightâ€Emitting Diodes. Advanced Materials, 2015, 27, 6418-6422.	21.0	89
11	MONITORING ENERGY BALANCE: Metabolites of Fatty Acid Synthesis as Hypothalamic Sensors. Annual Review of Biochemistry, 2005, 74, 515-534.	11.1	80
12	Quantitative Serum Proteomics from Surface Plasmon Resonance Imaging. Molecular and Cellular Proteomics, 2008, 7, 2464-2474.	3.8	71
13	Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PLoS ONE, 2015, 10, e0131429.	2.5	70
14	Targeting Peptideâ∈Based Probes for Molecular Imaging and Diagnosis. Advanced Materials, 2019, 31, e1804827.	21.0	68
15	Circulating microRNA-122 as a potential biomarker for liver injury. Molecular Medicine Reports, 2012, 5, 1428-32.	2.4	67
16	Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, hypothalamic neuropeptides, and UCP3. Biochemical and Biophysical Research Communications, 2004, 317, 301-308.	2.1	61
17	Effect of centrally administered C75, a fatty acid synthase inhibitor, on ghrelin secretion and its downstream effects. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3972-3977.	7.1	61
18	Antibodyâ€Mimetic Peptoid Nanosheet for Labelâ€Free Serumâ€Based Diagnosis of Alzheimer's Disease. Advanced Materials, 2017, 29, 1700057.	21.0	60

#	Article	IF	CITATIONS
19	Quantitative Liver-Specific Protein Fingerprint in Blood: A Signature for Hepatotoxicity. Theranostics, 2014, 4, 215-228.	10.0	47
20	Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor. Analytical Chemistry, 2015, 87, 8367-8372.	6.5	45
21	<p>Breakthroughs in medicine and bioimaging with up-conversion nanoparticles</p> . International Journal of Nanomedicine, 2019, Volume 14, 7759-7780.	6.7	41
22	Quantitative Proteomic Analysis of Cellular Resistance to the Nanoparticle Abraxane. ACS Nano, 2015, 9, 10099-10112.	14.6	40
23	SPR Imaging for High Throughput, Label-Free Interaction Analysis. Combinatorial Chemistry and High Throughput Screening, 2009, 12, 741-751.	1.1	39
24	Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics, $2015, 5, 1154-1165$.	10.0	34
25	Reconfigurable Peptide Nanotherapeutics at Tumor Microenvironmental pH. ACS Applied Materials & Lamp; Interfaces, 2017, 9, 30426-30436.	8.0	32
26	Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1). International Journal of Nanomedicine, 2017, Volume 12, 1685-1697.	6.7	32
27	Bimodal Imprint Chips for Peptide Screening: Integration of High-Throughput Sequencing by MS and Affinity Analyses by Surface Plasmon Resonance Imaging. Analytical Chemistry, 2014, 86, 3703-3707.	6.5	27
28	Antiamyloidogenic Activity of A \hat{I}^2 42-Binding Peptoid in Modulating Amyloid Oligomerization. Small, 2017, 13, 1602857.	10.0	17
29	Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging. PLoS Computational Biology, 2017, 13, e1005441.	3.2	15
30	Label-free detection microarray for novel peptide ligands screening base on MS–SPRi combination. Talanta, 2015, 134, 705-711.	5 . 5	13
31	Quantitative proteomic approaches for biomarker discovery. Proteomics - Clinical Applications, 2007, 1, 1036-1041.	1.6	11
32	Label-Free Detection with Surface Plasmon Resonance Imaging. Methods in Molecular Biology, 2011, 723, 321-333.	0.9	5
33	A novel refractive index detection method in voltage scanning surface plasmon resonance system. Sensors and Actuators B: Chemical, 2012, 169, 393-396.	7.8	5
34	High-Throughput Peptide Screening on a Bimodal Imprinting Chip Through MS-SPRi Integration. Methods in Molecular Biology, 2016, 1352, 111-125.	0.9	2
35	Mouse Organ-Specific Proteins and Functions. Cells, 2021, 10, 3449.	4.1	2